Robert Lyne joins PureTech as chief portfolio officer

27 September 2023

UK clinical-stage biotech PureTech Health (LSE: PRTC) today announced the appointment of Robert Lyne as chief portfolio officer.

Mr Lyne brings a decade of experience in international life science deals and portfolio management, along with governance and executive team leadership experience. Robert is expected to join PureTech by early January 2024.

Mr Lyne joins PureTech from Arix Bioscience, a transatlantic venture capital company focused on investing in innovative biotechnology companies, where he served as general counsel and chief operating officer before being appointed chief executive in April 2021.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK